ArticleProceedings of the National Academy of Sciences of the United States of America2007
Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 76 citations in OpenAlex.
- Influence of the Composition of Cationic Liposomes on the Performance of Cargo Immunostimulatory RNA.Pharmaceutics · 2023Article
- Extremes of age are associated with differences in the expression of selected pattern recognition receptor genes and ACE2, the receptor for SARS-CoV-2: implications for the epidemiology of COVID-19 disease.BMC medical genomics · 2021Article
- Late p65 nuclear translocation in glioblastoma cells indicates non-canonical TLR4 signaling and activation of DNA repair genes.Scientific reports · 2021Article
- CRL4The Journal of experimental medicine · 2018Article
- An Integrative Framework Reveals Signaling-to-Transcription Events in Toll-like Receptor Signaling.Cell reports · 2017Article
- TLR9 re-expression in cancer cells extends the S-phase and stabilizes p16(INK4a) protein expression.Oncogenesis · 2016Article
- Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.Cancer immunology, immunotherapy : CII · 2016Article
- The Yin and Yang of Toll-like receptors in cancer.Oncogene · 2014Review
- MyD88 and its divergent toll in carcinogenesis.Trends in immunology · 2013Review
- The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter.The Journal of experimental medicine · 2013Article
- TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity.Journal of virology · 2013Article
- Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.Cellular and molecular life sciences : CMLS · 2012Review
- Toll/interleukin-1 receptor domain-containing adapter inducing interferon-β mediates microglial phagocytosis of degenerating axons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- Targeting pattern recognition receptors in cancer immunotherapy.Targeted oncology · 2012Review
- Defective NF-κB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA.Cancer research · 2012Article
- Glucose activation of islets of Langerhans up-regulates Toll-like receptor 5: possible mechanism of protection.Clinical and experimental immunology · 2011Article
- Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1.PLoS pathogens · 2011Article
- A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy.The Journal of clinical investigation · 2011Article
- Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.Cancer research · 2011Article
- Innate inflammation and cancer: Is it time for cancer prevention?F1000 medicine reports · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
TRIF is an adaptor protein associated with the signaling by Toll-like receptor (TLR)3 and TLR4 for the induction of type I IFNs. Here, we demonstrate a mechanism by which TLR signaling controls cell proliferation and survival. We show that TLR3 and TLR4 can induce cell cycle entry via TRIF, which targets the cell cycle inhibitor p27(kip1) for relocalization, phosphorylation by cyclin/cdk complexes, and proteasome degradation. These events are antagonized by type I IFN induced by the TRIF pathway. Furthermore, in human dendritic cells treated with TLR3, TLR4, or TLR5 ligands, we demonstrate that IFN signaling modulates p27(kip1) degradation and apoptosis, identifying an immunoregulatory "switching" function of type I IFNs. These findings reveal a previously uncharacterized function of TLR signaling in cell proliferation and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.